RT Journal Article
SR Electronic
T1 LST-AI: a Deep Learning Ensemble for Accurate MS Lesion Segmentation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.23.23298966
DO 10.1101/2023.11.23.23298966
A1 Wiltgen, Tun
A1 McGinnis, Julian
A1 Schlaeger, Sarah
A1 Kofler, Florian
A1 Voon, CuiCi
A1 Berthele, Achim
A1 Bischl, Daria
A1 Grundl, Lioba
A1 Will, Nikolaus
A1 Metz, Marie
A1 Schinz, David
A1 Sepp, Dominik
A1 Prucker, Philipp
A1 Schmitz-Koep, Benita
A1 Zimmer, Claus
A1 Menze, Bjoern
A1 Rueckert, Daniel
A1 Hemmer, Bernhard
A1 Kirschke, Jan
A1 Mühlau, Mark
A1 Wiestler, Benedikt
YR 2024
UL http://medrxiv.org/content/early/2024/03/11/2023.11.23.23298966.abstract
AB Automated segmentation of brain white matter lesions is crucial for both clinical assessment and scientific research in multiple sclerosis (MS). Over a decade ago, we introduced an engineered lesion segmentation tool, LST. While recent lesion segmentation approaches have leveraged artificial intelligence (AI), they often remain proprietary and difficult to adopt. As an open-source tool, we present LST-AI, an advanced deep learning-based extension of LST that consists of an ensemble of three 3D-UNets.LST-AI explicitly addresses the imbalance between white matter (WM) lesions and non-lesioned WM. It employs a composite loss function incorporating binary cross-entropy and Tversky loss to improve segmentation of the highly heterogeneous MS lesions. We train the network ensemble on 491 MS pairs of T1w and FLAIR images, collected in-house from a 3T MRI scanner, and expert neuroradiologists manually segmented the utilized lesion maps for training. LST-AI additionally includes a lesion location annotation tool, labeling lesion location according to the 2017 McDonald criteria (periventricular, infratentorial, juxtacortical, subcortical). We conduct evaluations on 103 test cases consisting of publicly available data using the Anima segmentation validation tools and compare LST-AI with several publicly available lesion segmentation models.Our empirical analysis shows that LST-AI achieves superior performance compared to existing methods. Its Dice and F1 scores exceeded 0.62, outperforming LST, SAMSEG (Sequence Adaptive Multimodal SEGmentation), and the popular nnUNet framework, which all scored below 0.56. Notably, LST-AI demonstrated exceptional performance on the MSSEG-1 challenge dataset, an international WM lesion segmentation challenge, with a Dice score of 0.65 and an F1 score of 0.63—surpassing all other competing models at the time of the challenge. With increasing lesion volume, the lesion detection rate rapidly increased with a detection rate of >75% for lesions with a volume between 10mm3 and 100mm3.Given its higher segmentation performance, we recommend that research groups currently using LST transition to LST-AI. To facilitate broad adoption, we are releasing LST-AI as an open-source model, available as a command-line tool, dockerized container, or Python script, enabling diverse applications across multiple platforms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (Ethikkommission) of the School of Medicine and Health, TU Munich, approved the retrospective use of anonymized local MR studies of Multiple Sclerosis patients for this study (IRB# 2022-261-S-DFG-SR). Given the retrospective nature of our study (and anonymization of data), Informed Consent was waived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors